Evidence supporting the use of: Nicotinamide Mononucleotide
For the health condition: Strokes

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Nicotinamide Mononucleotide (NMN) is not a traditional remedy for stroke, but there is emerging scientific interest in its potential neuroprotective effects, particularly based on preclinical studies. NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a critical coenzyme involved in energy metabolism, DNA repair, and cell survival. In animal models of ischemic stroke, NMN administration has been shown to increase NAD+ levels in the brain, reduce infarct size, and improve neurological outcomes. These effects are thought to be related to enhanced mitochondrial function, reduced oxidative stress, and modulation of inflammation and cell death pathways. Despite promising results in rodents, direct clinical evidence in humans is currently lacking. There are no large-scale, peer-reviewed clinical trials demonstrating that NMN supplementation improves outcomes after stroke in humans. Most of the available data is limited to animal studies and in vitro experiments, and the translation of these findings to clinical practice remains speculative. As such, while there is a scientific rationale and preclinical evidence suggesting NMN could be beneficial in stroke, these findings are preliminary. At present, NMN should not be considered an established therapy for stroke, and its use for this condition is not supported by high-level clinical evidence.

More about Nicotinamide Mononucleotide
More about Strokes

Products containing Nicotinamide Mononucleotide

We currently have no products on Vitabase that contain this ingredient.